Orismilast for Eczema: ADESOS Missed Its Primary EASI Comparison Despite Secondary Signals

November 9, 2026

Dr. Arsy #003 white 4 oz (120 g) jar in an original table-tennis scene; AI-created editorial illustration.

DOCTOR’S NOTES · ECZEMA EVIDENCE

A trial can miss its primary comparison while finding encouraging secondary outcomes. Orismilast’s ADESOS study illustrates why a summary should tell you both, rather than treating every endpoint as interchangeable.

What ADESOS tested

The primary study abstract, linked to the 2025 journal publication, describes 233 adults with moderate-to-severe atopic dermatitis randomized to three twice-daily oral doses or placebo for 16 weeks. The study took place across 48 centers in Europe and the United States. Orismilast inhibits PDE4B/D; this was a drug study, not a trial of a retail moisturizer.

Study arm	Randomized participants
20 mg twice daily	58
30 mg twice daily	61
40 mg twice daily	59
Placebo	55

Start with the planned primary outcome

The primary endpoint was percentage change in EASI, a score of eczema extent and severity. All groups improved from baseline, but active-treatment comparisons with placebo did not reach statistical significance at week 16. Improvement on treatment is therefore not the same statement as a demonstrated advantage over the control.

The abstract reports significant secondary clearance responses for the 20-mg and 40-mg groups: clear or almost clear on the investigator scale, with at least a two-point improvement. It also reports an early itch signal at week two. Those outcomes address different questions and time points. An early itch response cannot be substituted for the primary week-16 EASI result.

Why the sponsor headline needs its own label

The September 25, 2024 sponsor announcement emphasized clearance findings across all three doses. The later peer-reviewed abstract specifically identifies significant clearance results for 20 and 40 mg. These summaries should not be merged into a single claim that every dose succeeded on the published primary endpoint.

A press release and a paper may emphasize different analyses. Without establishing the exact analysis underlying each statement, readers should retain the distinction rather than invent an explanation for the difference. This article relies on the primary abstract for the principal result; an inaccessible full paper is not being represented as fully reviewed.

What the study cannot decide for an individual

Dose-ranging research helps select regimens for future studies. It does not mean a person should choose an experimental dose based on which secondary number looks best. Several dose arms and endpoints also make it important to ask about prespecified analyses, missing data, multiplicity and tolerability before turning a signal into a broad promise.

The authors describe a safety profile consistent with the PDE4 class and no major new safety concerns. A 16-week experience cannot establish universal tolerance or long-term comparative safety. Sponsor-employed authors are among the study team; the company announcement is identified as sponsor communication.

For a practical consultation, identify your priority—skin extent, itch, sleep or functioning—and ask for evidence for that exact outcome. Do not alter prescribed care based on a research headline. Our DAMASK analysis shows why another oral trial’s primary endpoint and analysis population also need explicit labels.

Where daily moisture care fits

Dr. Arsy Moisturizer #003, 4 oz (120 g) is a cosmetic moisturizer for hydration, moisture-barrier support and dry-skin comfort. It does not treat, cure or prevent eczema and was not the intervention in this research. These findings do not establish infant suitability or pediatric efficacy for #003. A child’s clinician can advise on appropriate moisture care.